Ursodeoxycholic acid versus phenobarbital for cholestasis in the Neonatal Intensive Care Unit.

Tamorah R LewisSimisola KuyeAshley Sherman

Published in: BMC pediatrics (2018)

Phenobarbital, as compared to ursodiol, has limited efficacy for the reduction of direct bilirubin in neonates and young infants with cholestasis. Given new data regarding the potential neurotoxicity of phenobarbital in the developing brain, providers may choose to avoid phenobarbital in the treatment of cholestasis in infants.

Keyphrases

drug induced
white matter
electronic health record
big data
middle aged
low birth weight
climate change
combination therapy
human health
deep learning
replacement therapy
subarachnoid hemorrhage